LOG IN
SIGN UP
MARKET
FUSN
FUSN
Fusion Pharmaceuticals Inc.
NASDAQ
Real-time Quotes | Nasdaq Last Sale
2.040
-0.150
-6.85%
Closed 16:16 08/09 EDT
OPEN
2.290
PREV CLOSE
2.190
HIGH
2.290
LOW
2.010
VOLUME
72.96K
TURNOVER
--
52 WEEK HIGH
9.50
52 WEEK LOW
2.010
MARKET CAP
88.42M
P/E (TTM)
-1.0490
1D
5D
1M
3M
1Y
5Y
Fusion Pharmaceuticals Inc. (FUSN) Reports Q2 Loss, Tops Revenue Estimates
Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of 16.98% and 3.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 22h ago
BRIEF-Fusion Pharmaceuticals reports Q2 results
BRIEF-Fusion Pharmaceuticals reports Q2 results
Reuters · 22h ago
BRIEF-Fusion Pharmaceuticals Inc Announces Second Quarter 2022 Financial Results
BRIEF-Fusion Pharmaceuticals Inc Announces Second Quarter 2022 Financial Results
Reuters · 23h ago
Fusion Pharmaceuticals Announces Second Quarter 2022 Financial Results and Clinical Program Updates
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the second quarter ended June 30, 2022 and provided an up...
PR Newswire · 23h ago
Gain Therapeutics, Inc. (GANX) Expected to Beat Earnings Estimates: Should You Buy?
Gain Therapeutics, Inc. (GANX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 6d ago
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the compensation committee of the Company's Board of Directors granted sto...
CNW Group · 08/02 20:45
Will Fusion Pharmaceuticals Inc. (FUSN) Report Negative Q2 Earnings? What You Should Know
Fusion Pharmaceuticals Inc. (FUSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 08/02 14:00
We're Keeping An Eye On Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Simply Wall St. · 07/29 10:24
No Data
Learn about the latest financial forecast of FUSN. Analyze the recent business situations of Fusion Pharmaceuticals Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 6 analysts
Strong Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average FUSN stock price target is 16.25 with a high estimate of 19.00 and a low estimate of 12.00.
Current 2.040
EPS
Actual
Estimate
-0.50-0.38-0.25-0.13
Institutional Holdings
Institutions: 54
Institutional Holdings: 34.77M
% Owned: 80.21%
Shares Outstanding: 43.34M
TypeInstitutionsShares
Increased
4
1.55M
New
0
0
Decreased
4
984.58K
Sold Out
3
14.16K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.83%
Pharmaceuticals & Medical Research
-0.22%
Key Executives
Non-Executive Chairman/Independent Director
Barbara Duncan
President
Mohit Rawat
Chief Executive Officer/Founder/Director
John Valliant
Chief Financial Officer
John Crowley
Chief Technology Officer
Eric Burak
Chief Scientific Officer
Christopher Leamon
Independent Director
Donald Bergstrom
Independent Director
Pablo Cagnoni
Independent Director
Johan Christenson
Independent Director
Steven Gannon
Independent Director
Chau Khuong
Independent Director
Philina Lee
Independent Director
Heather Preston
No Data
No Data
About FUSN
Fusion Pharmaceuticals Inc. is a Canada-based clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. The Company has developed its Targeted Alpha Therapies (TAT) platform to enable it to connect alpha-particle emitting isotopes to various targeting molecules to selectively deliver the alpha-particle payloads to tumors. Its TAT platform is underpinned by its research and insights into the underlying chemistry and biology of alpha emitting radiopharmaceuticals; its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain, and its Fast-Clear linker technology used in conjunction with antibody-based targeting molecules, and development of imaging diagnostics. Its lead product candidate, FPI-1434, utilizes its Fast-Clear linker to connect a humanized monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF-1R), with actinium-225 or 225Ac.
Webull offers kinds of Fusion Pharmaceuticals Inc stock information, including NASDAQ:FUSN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FUSN stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading FUSN stock methods without spending real money on the virtual paper trading platform.